Caption Management’s ImmunityBio IBRX Stock Holding History

Caption Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.67K	Buy	+1,000	New	+$6.85K	﹤0.01%	1468
2025 Q4	–	Sell	-46,300	Closed	-$114K	–	1807
2025 Q3	$114K	Buy	46,300 +31,300	+209%	+$80.6K	﹤0.01%	1521
2025 Q2	$39.6K	Sell	15,000 -10,000	-40%	-$26.9K	﹤0.01%	1351
2025 Q1	$75.3K	Buy	+25,000	New	+$75.8K	﹤0.01%	1376
2024 Q4	–	Sell	-26,032	Closed	-$108K	–	1619
2024 Q3	$96.8K	Hold	26,032	–	–	﹤0.01%	1134
2024 Q2	$165K	Sell	26,032 -47,622	-65%	-$314K	﹤0.01%	978
2024 Q1	$396K	Buy	+73,654	New	+$334K	0.01%	913

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caption Management's IBRX Position: Q1 2026 in Review

Caption Management opened a new position in ImmunityBio (IBRX) in Q1 2026: 1,000 shares worth $7.67K. The stake represents ﹤0.01% of the portfolio and ranks #1468 among its holdings. This is a return to the name: Caption Management previously reported a position in IBRX as recently as Q3 2025.

Caption Management first reported a position in IBRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $396K in Q1 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Caption Management held 1,000 shares of ImmunityBio worth $7.67K as of Q1 2026.
ImmunityBio was a new Caption Management position in Q1 2026.
ImmunityBio made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1468 holding.
Caption Management first reported a position in ImmunityBio in Q1 2024 and has held it in 7 quarters since.
Caption Management's ImmunityBio position peaked at $396K in Q1 2024.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.